Improve Strategic Study Design
Choosing appropriate endpoints and designing and powering trials are just two examples of the many make-or-break decisions in the planning phase that impact future trial results. Cogstate has the expertise and extensive data sets to advise your team on vital study considerations, help you answer key drug development questions, and reduce risk and uncertainty.
|Leverage Insights from Key Landmark Studies
Cogstate is at the forefront of Alzheimer’s research via participation in several key longitudinal public private partnership (PPP) studies such as secondary prevention trials including A4 and DIAN, as well as registries and natural history studies including AIBL, ADNI, BHR, and the APT Webstudy, many of which offer open data sharing to advance collaborative research.
|Gain Study Design Guidance from Cognitive Science Experts
Utilizing open data sets made available through our involvement in PPPs, Cogstate scientists are able to advise study teams on endpoint selection, powering decisions, and interpretation of study results supportive of product efficacy, safety, and differentiating claims.
|Develop Go/No-Go Decision-Making Frameworks
Leveraging robust Go/No-Go decision-making criteria has the potential to increase the efficiency of AD drug development. While the process of determining an appropriate strategy may be initially time-consuming, it is well worth the efforts. Cogstate can help teams develop these strategies.